Cagrilintide 10mg

Description

Cagrilintide 10mg is a long-acting amylin analogue being studied extensively in metabolic and appetite-regulation research.

Amylin is a naturally occurring hormone released alongside insulin after food intake and participates in signaling related to satiety, gastric activity, and energy intake. Cagrilintide was designed to provide prolonged activity at amylin-related receptors, making it particularly interesting to researchers studying appetite regulation and metabolic signaling.

Cagrilintide has attracted substantial attention both as a standalone compound and in combination with semaglutide in the investigational therapy known as CagriSema. Phase 3 research has evaluated cagrilintide in people with overweight and obesity, while additional clinical-development programs continue to examine the broader potential of amylin-based therapies. 

Common research areas: amylin signaling, appetite regulation, satiety pathways, metabolic signaling, energy intake, and body-weight regulation.

Product Strength: 10mg

As of August 2026, cagrilintide remains an investigational compound rather than an FDA-approved standalone medication. Novo Nordisk continues to list cagrilintide within its research and development pipeline.